La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
83 hedge funds and large institutions have $286M invested in La Jolla Pharmaceutical Company in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 24 reducing their positions, and 13 closing their positions.
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
6% more funds holding
Funds holding: 78 → 83 (+5)
4% more call options, than puts
Call options by funds: $389K | Put options by funds: $374K
8% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 24
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
57% less capital invested
Capital invested by funds: $670M → $286M (-$384M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$7.38M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$4.64M |
| 3 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$1.91M |
| 4 |
SIM
Spark Investment Management
New York
|
+$1.85M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.7M |
| 2 |
RI
RTW Investments
New York
|
-$14M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.5M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.03M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.91M |
LJPC Hedge Fund Activity: Q4 2018 in Review
83 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2018, worth a combined $286M — down 57% from $670M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new LJPC positions and 13 closed out — a net gain of 5 holders — while 22 added to existing stakes and 24 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $7.38M. The largest seller was State Street, cutting an estimated $18.7M.
- 83 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2018, up from 78 in Q3 2018.
- Funds reported $286M of La Jolla Pharmaceutical Company stock for Q4 2018, down 57% quarter-over-quarter.
- 18 funds opened new La Jolla Pharmaceutical Company positions in Q4 2018 and 13 closed out, a net change of +5 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q4 2018 was Millennium Management, an estimated $7.38M added.
- The largest La Jolla Pharmaceutical Company seller in Q4 2018 was State Street, an estimated $18.7M sold.
Based on aggregated 13F filings for Q4 2018.